QELBREE

Peak

viloxazine hydrochloride

Supernus Pharmaceuticals

NDAORALCAPSULE, EXTENDED RELEASE

Approved

Apr 2021

Lifecycle

Peak

Competitive Pressure

0/100

Loss of Exclusivity

LOE Date

Apr 2, 2035

110 months away

Patent Expiry

Apr 2, 2035

Exclusivity Expiry

Apr 2, 2026

Patent Records (5)

Patent #	Expiry	Type	Use Code
11324753	Sep 4, 2029		U-727
11458143	Sep 4, 2029		U-727
12121523	Sep 4, 2029		U-727
9358204	Feb 7, 2033	Product	—
9603853	Feb 7, 2033		U-727

Company

Supernus Pharmaceuticals

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers